drugset / Trial / NCT05146154
Impact of Obesity on the Pharmacokinetics of Imipenem-Relebactam in ICU Patients
Non-randomizedSingle-groupOpen-labelOther
Summary
This study is an open-label, multiple-dose pharmacokinetic study of imipenem-relebactam conducted in 12 non-infected, obese ICU patients.
Timeline
- Start
- 2023-01-01
- Primary completion
- 2023-06-01
- Completion
- 2024-01-01
Outcome
Outcome not reported
Stopped: “Investigator is no longer at University of Illinois”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imipenem/Cilastatin/Relebactam | Other / unclassified | 1.25 g | — |